UBS Reaffirms Their Hold Rating on Bayer (0P6S)
In a report released yesterday, Matthew Weston from UBS maintained a Hold rating on Bayer. The company’s shares closed yesterday at €41.52.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Weston is a 4-star analyst with an average return of 11.6% and an 81.05% success rate. Weston covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Roche Holding AG, and GlaxoSmithKline.
In addition to UBS, Bayer also received a Hold from TipRanks – DeepSeek’s DeepSeek Health Care GB in a report issued today. However, on January 13, Kepler Capital maintained a Buy rating on Bayer (LSE: 0P6S).
Based on Bayer’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of €9.66 billion and a GAAP net loss of €963 million. In comparison, last year the company earned a revenue of €9.97 billion and had a GAAP net loss of €4.18 billion
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
- Bayer, Souffle Therapeutics report global licensing agreement for siRNA therapy
- Barclays upgrades Bayer to Overweight on possible litigation overhang resolution
